Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

9.15% (1Y)

Market Cap	15.50B
Revenue (ttm)	2.51B
Net Income (ttm)	698.20M
Shares Out	1.67B
EPS (ttm)	0.42
PE Ratio	22.26
Forward PE	n/a
Dividend	0.30 (3.31%)
Ex-Dividend Date	May 23, 2025

Volume	26,138,268
Average Volume	37,413,060
Open	9.11
Previous Close	9.29
Day's Range	9.11 - 9.34
52-Week Range	7.38 - 11.55
Beta	0.49
RSI	64.29
Earnings Date	Aug 22, 2025

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 2,647
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300009

Financial Performance

In 2024, SHE:300009's revenue was 2.54 billion, a decrease of -11.51% compared to the previous year's 2.87 billion. Earnings were 706.95 million, a decrease of -16.56%.